Prescription and over-the-counter medicine
Bacitracin and neomycin and polymyxin b First approved as Lumi-Sporyn
Bacitracin and neomycin and polymyxin b (Lumi-Sporyn) is a prescription and over-the-counter medicine with an FDA approval on record since 1971. FDA's NDC Directory lists it from 1 generic labeler, and pharmacies paid $0.111 per gram (Triple antibiotic ointment) in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the bacitracin and neomycin and polymyxin b FDA label on DailyMed (effective December 1, 2025); the NDA 50417 record on Drugs@FDA; every bacitracin and neomycin and polymyxin b label on DailyMed.
Highlights of the record
FDA label of December 1, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageUse First aid to help prevent infection in minor cuts scrapes burns
Forms and strengths
- 3.5 mg/g
Ointment.
On the market
- Earliest approval on file
- May 10, 1971 Lumi-Sporyn, Casper Pharma Llc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 4 first April 19, 1954; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 1 of which 1 under generic applications, 0 under brand applications, repackagers included; 120 more under the over-the-counter monograph, without an application
Supply and safety
- Pharmacy cost (NADAC)
- $0.111 per gram Triple antibiotic ointment
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 0 since 2013 0 Class I among all firms' recalls; 2 more by firms not listed as its makers
- FAERS reports
- 13 through July 30, 2026
What is bacitracin and neomycin and polymyxin b used for?
From the label: indications and usageUse First aid to help prevent infection in minor cuts scrapes burns
Conditions named in the indications of bacitracin and neomycin and polymyxin b's FDA labels, with every medicine labeled for each:
From other bacitracin and neomycin and polymyxin b labelsPain: First aid to help prevent infection and temporarily relieve pain in minor cuts scrapes burns abrasions
FDA pharmacologic class: Aminoglycoside Antibacterial and Polymyxin-class Antibacterial.
Source: FDA drug label (Triple Antibiotic Ointment, Circle K), Lil' Drug Store Products, Inc., effective December 1, 2025 (SPL set 44e5107e-832a-2ce6-e063-6294a90a711d), via openFDA; the full label on DailyMed
Is there a generic for bacitracin and neomycin and polymyxin b (Lumi-Sporyn)?
The FDA approved the first generic bacitracin and neomycin and polymyxin b on April 19, 1954. 4 generic applications are approved; 1 of them carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists bacitracin and neomycin and polymyxin b from 1 labeler under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1971 earliest approval on file
- 1954 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for bacitracin and neomycin and polymyxin b (Lumi-Sporyn)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.111 per gram (Triple antibiotic ointment), up 4% from $0.106 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Triple antibiotic ointment (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Ft triple antibiotic ointment | Generic | $0.111 per gram | n/a | +4% |
| Gs first aid antibiotic ointment | Generic | $0.0888 per gram | n/a | +11% |
| Neomyc-bacit-polymix eye ointment | Generic | $4.70 per gram | n/a | -6% |
| Qc triple antibiotic ointment | Generic | $0.139 per gram | n/a | +2% |
| Triple antibiotic ointment | Generic | $0.111 per gram | n/a | +4% |
| Triple antibiotic ointment packet | Generic | $0.127 per packet | n/a | +2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has bacitracin and neomycin and polymyxin b been recalled?
The FDA's Enforcement Report lists 2 recalls naming bacitracin and neomycin and polymyxin b since 2013: 0 Class I (the most serious), 2 Class II, 0 Class III; 0 still ongoing. 2 of them are by firms that FDA's NDC Directory does not list as a maker of bacitracin and neomycin and polymyxin b and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| April 24, 2025 | Class II | KENIL HEALTHCARE PRIVATE LIMITED not a listed maker | CGMP Deviations |
| November 22, 2013 | Class II | Faria Limited LLC dba Sheffield Pharmaceuticals not a listed maker | Microbial Contamination of Non-Sterile Products: Elevated counts of gram positive rods were found during environmental testing |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What do FAERS reports show for bacitracin and neomycin and polymyxin b?
The FDA Adverse Event Reporting System holds 13 reports that list bacitracin and neomycin and polymyxin b among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1 are coded as a death and 1 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other aminoglycoside antibacterials
- the pharmacologic class, with prices and generics
- Bacitracin and neomycin and polymyxin b side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other